Naldemedine for Opioid-Induced Constipation
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 34,532 (estimated)
- Sponsor
- BioDelivery Sciences International · Industry
This trial is looking for patients experiencing constipation caused by opioid use. Participants will compare the effects of naldemedine to other medications for this condition.
You may be able to join if
- I am at least 18 years old
- I have received at least one prescription for naldemedine, lubiprostone, or naloxegol
- I have taken opioids at least two times in the past six months
- I have had enough opioid medication for at least 31 days in total
- I have been continuously covered by a health plan for at least six months
You may not be able to join if
- I have had a heart attack or stroke in the past 6 months
- I have received treatment for cancer or have been diagnosed with cancer pain in the past 6 months
- I have used methylnaltrexone, alvimopan, or naloxegol in the past 6 months
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.
Loading trial locations…